Search results for "Pulmonary embolism"


 
Results 81 - 90 of about 102 for "Pulmonary embolism".
Sort by: Relevance | Newest | Oldest

Pros, cons of prolonged anticoagulation after a clot

Experts debate about provoked vs. unprovoked venous thromboembolism, and whether a once-high-risk patient can have that status removed later.
https://immattersacp.org/archives/2020/02/pros-cons-of-prolonged-anticoagulation-after-a-clot.htm
1 Feb 2020

New warnings for gabapentinoids; other drugs approved

This column reviews details on recent recalls, warnings, and approvals.
https://immattersacp.org/archives/2020/02/new-warnings-for-gabapentinoids-other-drugs-approved.htm
1 Feb 2020

Stronger warning for montelukast; COVID-19 actions

This column reviews details on recent recalls, warnings, and approvals.
https://immattersacp.org/archives/2020/05/stronger-warning-for-montelukast-covid-19-actions.htm
1 May 2020

IDSA offers criteria on testing for COVID-19; new research looks at clots, treatments

The Infectious Diseases Society of America (IDSA) released guidance for COVID-19 testing among inpatients and outpatients, while studies offered further support for anticoagulation but showed no benefit from hydroxychloroquine or lopinavir-ritonavir.
https://immattersacp.org/weekly/archives/2020/05/12/1.htm
12 May 2020

MKSAP Quiz: 6 months of exertional dyspnea

A 46-year-old man is evaluated for 6 months of exertional dyspnea, fatigue, and ankle edema. Recently he experienced near-syncope walking up two flights of stairs. He has no other medical problems and takes no medications. Following a physical exam, transthoracic echocardiogram, and other tests, what is the most appropriate treatment?
https://immattersacp.org/weekly/archives/2020/06/09/3.htm
9 Jun 2020

Risk of re-infection, benefits of anticoagulation, cause of sex differences among COVID-19 research

Researchers published evidence of re-infection with SARS-CoV-2, anticoagulation was associated with halved inpatient mortality, recommendations were made on pulmonary embolism in COVID-19, and a study attributed differences in men's and women's outcomes to T cells.
https://immattersacp.org/weekly/archives/2020/09/01/2.htm
1 Sep 2020

Guidelines offer 28 recommendations for initial management, secondary prevention of DVT and PE

Among other recommendations, the new guidelines from the American Society of Hematology suggest offering home treatment to low-risk patients with deep venous thrombosis (DVT) or pulmonary embolism (PE).
https://immattersacp.org/weekly/archives/2020/10/20/5.htm
20 Oct 2020

Long-term anticoagulation after first unprovoked VTE associated with considerable bleeding risk

Results from a systematic review and meta-analysis provide a framework for clinicians and patients to balance the benefits and harms of extended anticoagulation for unprovoked venous thromboembolism (VTE).
https://immattersacp.org/weekly/archives/2021/09/14/4.htm
14 Sep 2021

Advice on monoclonal antibodies; new data on long-term COVID-19 symptoms, vaccine efficacy

The NIH offered guidance on prioritization when monoclonal antibodies can't be given to all eligible patients. Two studies looked at patients with persistent COVID-19 symptoms, and other research confirmed the safety and effectiveness of the vaccines, even with the delta variant.
https://immattersacp.org/weekly/archives/2021/09/14/2.htm
14 Sep 2021

Apixaban shows superior effectiveness, safety compared to rivaroxaban

For patients with venous thromboembolism, initiation of apixaban was associated with lower rates of recurrence and intracranial and gastrointestinal bleeding than rivaroxaban in a population-based cohort study.
https://immattersacp.org/weekly/archives/2021/12/07/2.htm
7 Dec 2021

Result Page: Prev   4   5   6   7   8   9   10   11   Next